Oleh Maksym Misichenko · Nasdaq ·
Apa yang dipikirkan agen AI tentang berita ini
CVS delivered a strong quarter with revenue above $100B and raised guidance, but investors should be cautious due to margin pressure in Pharmacy Services, integration struggles with Aetna, and potential headwinds from GLP-1 drugs and CMS Star Ratings volatility.
Risiko: CMS Star Ratings volatility leading to a drop in quality bonus payments
Peluang: CVS's pharmacy strength and integrated services amid Rite Aid's collapse
Analisis ini dihasilkan oleh pipeline StockScreener — empat LLM terkemuka (Claude, GPT, Gemini, Grok) menerima prompt identik dengan perlindungan anti-halusinasi bawaan. Baca metodologi →
Pendapatan teratasnya melebihi $100 miliar.
Perusahaan juga menaikkan panduan laba bersih tahunan yang disesuaikan.
Salah satu saham yang lebih sehat di sektor kesehatan pada hari Rabu adalah raja ritelnya, CVS Health (NYSE: CVS). Perusahaan merilis hasil kuartal pertamanya, dan investor gembira dengan kinerjanya. Berkat dua kali lipat pada fundamental utama, pelaku pasar mendorong saham CVS naik hampir 8% pada hari perdagangan itu.
CVS mencapai wilayah sembilan digit dengan pendapatan kuartal itu, yang sedikit melebihi $100 miliar. Itu mewakili peningkatan tahun-ke-tahun sebesar 6% -- cukup kuat untuk perusahaan sematang ini di ruang ritel.
Akankah AI menciptakan triliuner pertama di dunia? Tim kami baru saja merilis laporan tentang satu perusahaan yang kurang dikenal, yang disebut "Monopoli yang Sangat Diperlukan" yang menyediakan teknologi penting yang dibutuhkan Nvidia dan Intel. Lanjutkan »
Laba bersih berdasarkan prinsip akuntansi yang berlaku umum (GAAP) melonjak sebesar 66% menjadi sedikit di bawah $2,96 miliar. Atas dasar non-GAAP (disesuaikan), profitabilitas CVS adalah $2,57 per saham, naik dari hasil tahun sebelumnya sebesar $2,25.
Analis meremehkan potensi pertumbuhan perusahaan. Untuk kuartal tersebut, perkiraan pendapatan konsensus mereka hanya sedikit di atas $95 miliar, sementara ekspektasi laba per saham (EPS) yang disesuaikan secara kolektif adalah $2,21.
Dalam rilis pendapatannya, CVS mengatakan kesuksesan baru-baru ini didorong oleh kehadiran kuatnya di pasar farmasi dan struktur uniknya. Perusahaan mengutip CEO David Joyner yang mengatakan bahwa perusahaan "terus menyediakan apa yang paling diinginkan orang dari layanan kesehatan: pengalaman keterlibatan yang terhubung, nyaman, dan hemat biaya di seluruh koleksi bisnis kami yang unik."
Memperkuat dua kali lipat yang sangat meyakinkan pada proyeksi analis, CVS juga menaikkan panduan laba akhirnya. Perusahaan sekarang memproyeksikan EPS yang disesuaikan sebesar $7,30 hingga $7,50, jauh di atas kisaran sebelumnya sebesar $7 hingga $7,20. Untuk pendapatan, manajemen mengantisipasi jumlahnya setidaknya $405 miliar.
CVS tidak hanya lebih menonjol karena runtuhnya pesaing lama Rite Aid tahun lalu, tetapi juga mendapat manfaat dari serangkaian produk dan layanan yang sinergis untuk pelanggannya, seperti kata Joyner. Selain itu, populasi AS semakin menua dan semakin membutuhkan obat-obatan. Saya merasa selama CVS terus menempuh jalurnya saat ini dan tetap berada di atas pesaingnya, sahamnya akan berkinerja baik.
Ketika tim analis kami memiliki tips saham, mendengarkan bisa bermanfaat. Bagaimanapun, total imbal hasil rata-rata Stock Advisor adalah 950%* — kinerja yang mengalahkan pasar dibandingkan dengan 203% untuk S&P 500.
Mereka baru saja mengungkapkan apa yang mereka yakini sebagai 10 saham terbaik untuk dibeli investor saat ini, tersedia saat Anda bergabung dengan Stock Advisor.
**Imbal hasil Stock Advisor per 6 Mei 2026. *
Eric Volkman tidak memiliki posisi di saham mana pun yang disebutkan. The Motley Fool merekomendasikan CVS Health. The Motley Fool memiliki kebijakan pengungkapan.
Pandangan dan opini yang diungkapkan di sini adalah pandangan dan opini penulis dan tidak selalu mencerminkan pandangan dan opini Nasdaq, Inc.
Empat model AI terkemuka mendiskusikan artikel ini
"The earnings beat reflects operational stabilization rather than a fundamental shift in the company's long-term margin trajectory."
CVS’s 8% pop is a classic relief rally driven by clearing a low bar, but investors should look past the headline revenue beat. While the $100B top-line is impressive, the real story is the margin pressure in the Pharmacy Services segment and the ongoing integration struggles with Aetna. Raising guidance is a positive signal, but the company is still battling elevated medical loss ratios (MLR) that have plagued the entire managed care sector. At a forward P/E of roughly 9-10x, the market is pricing in a 'value trap' scenario. I am neutral because while the downside seems protected by the retail footprint, the path to sustained margin expansion remains obscured by rising drug costs and regulatory scrutiny.
If CVS successfully leverages its 'connected' healthcare ecosystem to drive down medical costs for its Aetna members, the current valuation could represent a significant discount to its long-term earnings power.
"CVS's scale in pharmacy services post-Rite Aid positions it to capture aging population tailwinds, with this quarter's results validating a near-term re-rating."
CVS (NYSE: CVS) crushed Q1 estimates with revenue over $100B (6% YoY growth, beating $95B consensus) and adjusted EPS of $2.57 versus $2.21 expected, driving an 8% stock surge. The company raised FY adjusted EPS guidance to $7.30-$7.50 (midpoint ~$7.40, up from prior $7.10 midpoint) and revenue to $405B+, underscoring pharmacy strength and integrated services amid Rite Aid's collapse. Aging demographics bolster demand, but article downplays Health Care Benefits pressures like elevated medical loss ratios (MLR)—omitted context from prior quarters where costs eroded margins. Near-term momentum favors re-rating, but sustainability hinges on cost containment.
Despite the beat-and-raise, modest guidance growth (~4% EPS midpoint hike) reflects persistent headwinds in PBM rebates and retail pharmacy margins squeezed by e-commerce rivals, potentially capping upside if Medicare Advantage changes accelerate utilization.
"CVS beat on both lines and raised guidance, but the article doesn't distinguish between one-time Rite Aid synergies and durable margin expansion, leaving the sustainability of the raised EPS outlook unclear."
CVS beat on revenue ($100.1B vs. $95B consensus) and adjusted EPS ($2.57 vs. $2.21), then raised FY guidance to $7.30-$7.50 adjusted EPS. The 8% pop is justified on execution. However, the article conflates operational success with stock upside without stress-testing margins. Adjusted EPS grew 14% YoY ($2.25 to $2.57), but revenue grew only 6%. That's margin expansion—likely from pharmacy mix and cost discipline post-Rite Aid. The risk: if this margin gain is cyclical (Rite Aid absorption, one-time benefits) rather than structural, guidance raises could disappoint. Also missing: PBM margin pressure, GLP-1 drug adoption headwinds to pharmacy volumes, and whether $405B+ revenue guidance assumes pricing or volume.
The article ignores that CVS's PBM (pharmacy benefit management) arm faces structural margin compression from drug pricing reform and GLP-1 adoption reducing fill counts—operational wins in retail may mask deterioration in the higher-margin PBM segment, making the guidance raise a false comfort.
"Sustainable upside for CVS stock depends on durable margin expansion and market-share gains in core businesses, not just a quarterly beat."
CVS delivered a notable beat: revenue above $100B, GAAP net income up meaningfully, and raised full-year guidance, signaling resilience in a mature retail/healthcare model. Yet the strength may hinge on near-term mix and one-offs rather than a structural shift. Key risks include PBM margin pressure from pricing headwinds and payer dynamics, competition from Walgreens/Walmart, and potential regulatory changes impacting reimbursements. Integration progress from legacy acquisitions and cost-containment efforts will matter more than one-quarter relief. If policy shifts or slower-than-expected efficiency gains emerge, multiple expansion could stall even with a strong quarter. Investors should test sensitivity to reimbursement-rate changes and competitive intensity.
The rally could be overextended if the guidance assumes favorable PBM pricing and Medicare dynamics that aren't sustainable, and any delay in synergies or a policy reversal could reprice CVS quickly.
"CVS's valuation risk is tied to CMS Star Ratings and quality bonus payments, which outweigh retail operational improvements."
Claude, you’re right to highlight the PBM margin compression, but you’re missing the second-order effect of GLP-1s: they are a massive volume driver for CVS’s specialty pharmacy, not just a fill-count headwind. The real risk isn't the drug mix; it's the CMS Star Ratings volatility. If CVS’s Aetna plans lose their 4-star status, the resulting drop in quality bonus payments will dwarf any retail operational gains. The market is ignoring this looming revenue cliff.
"FTC PBM rules pose a larger, quantifiable margin threat than Star Ratings volatility."
Gemini, your Star Ratings point is sharp, but it overlooks CVS's Q1 disclosure of stable Aetna plan ratings (avg 4.1 stars). The unmentioned cliff is FTC's PBM rebate transparency rules, effective 2025, which could slash CVS Caremark margins by 100-200bps per analyst estimates—eroding the EPS guide's foundation faster than retail gains can offset.
"FTC rebate rules matter only if CVS's guidance doesn't already price them in—need clarity on what management assumed."
Grok's FTC rebate transparency rule is material, but the 100-200bps margin hit assumes CVS can't pass costs downstream. PBM contracts are renegotiated annually—CVS has leverage with Aetna integration and scale. The real test: does guidance assume rebate compression already, or is it baked into the $7.30-$7.50 range? If the latter, the rule becomes a non-event. If the former, we're missing what offset it in the raise.
"FTC rebate transparency could erode PBM margins, but the magnitude is uncertain and may be offset by pass-throughs; the bigger risk is policy impact or slower Aetna integration that could still push EPS below guidance."
Grok's 100-200bp PBM margin hit from FTC rebate transparency is plausible but not guaranteed; rebates are renegotiated annually and there are pass-throughs and leverage in CVS Caremark that can cushion reductions. The bigger, underplayed risk remains Star Ratings/quality bonus dependence and GLP-1-driven demand shifts. If the FTC rule lands hard or Aetna integration slows, EPS could miss guidance even if retail margins hold.
CVS delivered a strong quarter with revenue above $100B and raised guidance, but investors should be cautious due to margin pressure in Pharmacy Services, integration struggles with Aetna, and potential headwinds from GLP-1 drugs and CMS Star Ratings volatility.
CVS's pharmacy strength and integrated services amid Rite Aid's collapse
CMS Star Ratings volatility leading to a drop in quality bonus payments